Table 2.
Quantitative summary of gross observations in MIA-induced osteoarthritic rats treated with GCSB-5.
| Control | MIA | |||||
|---|---|---|---|---|---|---|
| Vehicle | GCSB-5 (mg/kg) | Diclofenac | ||||
| 300 | 600 | 5 mg/kg | ||||
| Swelling | ||||||
| No change | 0 | 10/10 | 0/10 | 1/10 | 1/10 | 0/10 |
| Mild | 1 | 0/10 | 3/10 | 8/10 | 6/10 | 8/10 |
| Severe | 2 | 0/10 | 7/10 | 1/10 | 3/10 | 2/10 |
| Average score | 0.0 ± 0.0 | 1.7 ± 0.2a | 1.0 ± 0.2a,b | 1.2 ± 0.2a | 1.2 ± 0.1a | |
|
| ||||||
| Limping | ||||||
| No change | 0 | 10/10 | 0/10 | 6/10 | 5/10 | 5/10 |
| Mild | 1 | 0/10 | 7/10 | 4/10 | 5/10 | 5/10 |
| Severe | 2 | 0/10 | 3/10 | 0/10 | 0/10 | 0/10 |
| Average score | 0.0 ± 0.0 | 1.3 ± 0.2a | 0.4 ± 0.2c | 0.5 ± 0.2c | 0.5 ± 0.2c | |
GCSB-5 or diclofenac was treated daily for 14 days after 2 weeks of OA induction by intra-articular injection of MIA.
aDenotes significant differences (P < 0.01) versus the control group.
b,cDenote significant differences (P < 0.05, P < 0.01) versus the vehicle-treated MIA group.